Brought to you by 
Adolor licenses opioid patents from Lilly
21 Jul 2003
Executive Summary
Adolor Corp. (pain drugs and mitigation of analgesics' side effects) has obtained from Eli Lilly an exclusive license to compounds and certain processes relating to peripherally selective opioid antagonists. The deal includes six issued US patents, the foreign equivalents, and know-how.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Adolor licenses opioid patents from Lilly
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice